The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagata, Y.
Right arrow Articles by Shiku, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagata, Y.
Right arrow Articles by Shiku, H.

The Journal of Immunology, Vol 159, Issue 3 1336-1343, Copyright © 1997 by American Association of Immunologists

ARTICLES

Peptides derived from a wild-type murine proto-oncogene c-erbB- 2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts

Y Nagata, R Furugen, A Hiasa, H Ikeda, N Ohta, K Furukawa, H Nakamura, K Furukawa, T Kanematsu and H Shiku
Second Department of Surgery, Nagasaki University School of Medicine, Japan.

In this analysis, we examined whether peptides derived from a wild-type murine proto-oncogene, c-erbB-2, function as tumor rejection Ags. Expression of murine c-erbB-2 examined by means of reverse transcription-PCR was observed in several normal adult tissues, such as intestine, kidney, and testis. We then transduced human and murine c- erbB-2 cDNA into two mutually noncross-reactive fibrosarcoma lines of BALB/c origin, CMS7 and CMS17. In BALB/c mice immunized with CMS17HE (CMS17 transduced with human c-erbB-2 cDNA), the growth of subsequently challenged CMS7HE (CMS7 transduced with human c-erbB-2 cDNA) was significantly suppressed. CTL against human c-erbB-2-expressing cells were generated from BALB/c spleen cells in vivo and in vitro sensitized by CMS17HE. The CTL activity was also directed against murine c-erbB-2- expressing cells, CMS7ME and CMS17ME, and was blocked by anti-CD8 or anti-Kd mAbs. A series of peptides of human or murine c-erbB-2 compatible with the Kd binding motif was synthesized. The CTL were reactive with P1.HTR (H-2d) pulsed with three of these peptides, p63-71 (human c-erbB-2 derived), p63-71(A) (murine c-erbB-2 derived), and p780- 788 (common for human and murine c-erbB-2). Spleen cells immunized in vivo and in vitro with syngeneic spleen cells pulsed with these peptides became cytotoxic for CMS17HE and/or CMS17ME, but not CMS17neo (CMS17 transduced with control vector). The growth of CMS7ME was suppressed in mice immunized with the murine c-erbB-2-derived peptide, p63-71(A) or p780-788. There was no apparent pathologic change in mice that rejected CMS7ME after vaccination with these peptides.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
H. Nishikawa, T. Kato, M. Hirayama, Y. Orito, E. Sato, N. Harada, S. Gnjatic, L. J. Old, and H. Shiku
Regulatory T Cell-Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling
Cancer Res., July 15, 2008; 68(14): 5948 - 5954.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Li, S. Andreansky, G. Helguera, M. Sepassi, N. Janikashvili, J. Cantrell, C. L. LaCasse, N. Larmonier, M. L. Penichet, and E. Katsanis
A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model
Mol. Cancer Ther., March 1, 2008; 7(3): 721 - 729.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-J. Ko, Y.-J. Kim, Y.-S. Kim, W.-S. Chang, S.-Y. Ko, S.-Y. Chang, S. Sakaguchi, and C.-Y. Kang
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
Cancer Res., August 1, 2007; 67(15): 7477 - 7486.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Spadaro, C. Curcio, A. Varadhachary, F. Cavallo, J. Engelmayer, P. Blezinger, F. Pericle, and G. Forni
Requirement for IFN-{gamma}, CD8+ T Lymphocytes, and NKT Cells in Talactoferrin-Induced Inhibition of neu+ Tumors
Cancer Res., July 1, 2007; 67(13): 6425 - 6432.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. J. Czerniecki, G. K. Koski, U. Koldovsky, S. Xu, P. A. Cohen, R. Mick, H. Nisenbaum, T. Pasha, M. Xu, K. R. Fox, et al.
Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion
Cancer Res., February 15, 2007; 67(4): 1842 - 1852.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Nava-Parada, G. Forni, K. L. Knutson, L. R. Pease, and E. Celis
Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast Tumors
Cancer Res., February 1, 2007; 67(3): 1326 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Kitano, S. Kageyama, Y. Nagata, Y. Miyahara, A. Hiasa, H. Naota, S. Okumura, H. Imai, T. Shiraishi, M. Masuya, et al.
HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan
Clin. Cancer Res., December 15, 2006; 12(24): 7397 - 7405.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Rolla, C. Nicolo, S. Malinarich, M. Orsini, G. Forni, F. Cavallo, and F. Ria
Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice
J. Immunol., December 1, 2006; 177(11): 7626 - 7633.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Ambrosino, M. Spadaro, M. Iezzi, C. Curcio, G. Forni, P. Musiani, W.-Z. Wei, and F. Cavallo
Immunosurveillance of erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance.
Cancer Res., August 1, 2006; 66(15): 7734 - 7740.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Chung, B.-S. Kim, Y.-J. Kim, H.-J. Ko, S.-Y. Ko, D.-H. Kim, and C.-Y. Kang
CD1d-Restricted T Cells License B Cells to Generate Long-Lasting Cytotoxic Antitumor Immunity In vivo.
Cancer Res., July 1, 2006; 66(13): 6843 - 6850.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Pannellini, M. Spadaro, E. Di Carlo, E. Ambrosino, M. Iezzi, A. Amici, P. L. Lollini, G. Forni, F. Cavallo, and P. Musiani
Timely DNA Vaccine Combined with Systemic IL-12 Prevents Parotid Carcinomas before a Dominant-Negative p53 Makes Their Growth Independent of HER-2/neu Expression.
J. Immunol., June 15, 2006; 176(12): 7695 - 7703.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. D. Gritzapis, L. G. Mahaira, S. A. Perez, N. T. Cacoullos, M. Papamichail, and C. N. Baxevanis
Vaccination with Human HER-2/neu (435-443) CTL Peptide Induces Effective Antitumor Immunity against HER-2/neu-Expressing Tumor Cells In vivo.
Cancer Res., May 15, 2006; 66(10): 5452 - 5460.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Mitaksov and D. H. Fremont
Structural Definition of the H-2Kd Peptide-binding Motif
J. Biol. Chem., April 14, 2006; 281(15): 10618 - 10625.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Helguera, J. A. Rodriguez, and M. L. Penichet
Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.
Mol. Cancer Ther., April 1, 2006; 5(4): 1029 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Nishikawa, T. Kato, I. Tawara, H. Ikeda, K. Kuribayashi, P. M. Allen, R. D. Schreiber, L. J. Old, and H. Shiku
IFN-{gamma} Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response
J. Immunol., October 1, 2005; 175(7): 4433 - 4440.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Rohrbach, R. Weth, M. Kursar, A. Sloots, H.-W. Mittrucker, and W. S. Wels
Targeted Delivery of the ErbB2/HER2 Tumor Antigen to Professional APCs Results in Effective Antitumor Immunity
J. Immunol., May 1, 2005; 174(9): 5481 - 5489.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Quaglino, M. Iezzi, C. Mastini, A. Amici, F. Pericle, E. Di Carlo, S. M. Pupa, C. De Giovanni, M. Spadaro, C. Curcio, et al.
Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neu Transgenic Mice
Cancer Res., April 15, 2004; 64(8): 2858 - 2864.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cuadros, A. L. Dominguez, G. I. Frost, P. Borgstrom, and J. Lustgarten
Cooperative Effect between Immunotherapy and Antiangiogenic Therapy Leads to Effective Tumor Rejection in Tolerant Her-2/neu Mice
Cancer Res., September 15, 2003; 63(18): 5895 - 5901.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Renard, L. Sonderbye, K. Ebbehoj, P. B. Rasmussen, K. Gregorius, T. Gottschalk, S. Mouritsen, A. Gautam, and D. R. Leach
HER-2 DNA and Protein Vaccines Containing Potent Th Cell Epitopes Induce Distinct Protective and Therapeutic Antitumor Responses in HER-2 Transgenic Mice
J. Immunol., August 1, 2003; 171(3): 1588 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. K. Dakappagari, J. Pyles, R. Parihar, W. E. Carson, D. C. Young, and P. T. P. Kaumaya
A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses
J. Immunol., April 15, 2003; 170(8): 4242 - 4253.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. M. Ercolini, J.-P. H. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee
Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice
J. Immunol., April 15, 2003; 170(8): 4273 - 4280.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Ikuta, N. Katayama, L. Wang, T. Okugawa, Y. Takahashi, M. Schmitt, X. Gu, M. Watanabe, K. Akiyoshi, H. Nakamura, et al.
Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy
Blood, May 15, 2002; 99(10): 3717 - 3724.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Ota, T. Ono, A. Morita, A. Uenaka, M. Harada, and E. Nakayama
Cellular Processing of a Multibranched Lysine Core with Tumor Antigen Peptides and Presentation of Peptide Epitopes Recognized by Cytotoxic T Lymphocytes on Antigen-presenting Cells
Cancer Res., March 1, 2002; 62(5): 1471 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Nishikawa, K. Tanida, H. Ikeda, M. Sakakura, Y. Miyahara, T. Aota, K. Mukai, M. Watanabe, K. Kuribayashi, L. J. Old, et al.
Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity
PNAS, November 20, 2001; (2001) 251547298.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Piechocki, S. A. Pilon, and W.-Z. Wei
Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-2
J. Immunol., September 15, 2001; 167(6): 3367 - 3374.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. L. Yip, G. Smith, J. Koch, S. Dubel, and R. L. Ward
Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design
J. Immunol., April 15, 2001; 166(8): 5271 - 5278.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Rovero, A. Amici, E. D. Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P.-L. Lollini, et al.
DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice
J. Immunol., November 1, 2000; 165(9): 5133 - 5142.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. D. Weinberg, M.-M. Rivera, R. Prell, A. Morris, T. Ramstad, J. T. Vetto, W. J. Urba, G. Alvord, C. Bunce, and J. Shields
Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity
J. Immunol., February 15, 2000; 164(4): 2160 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. , S. , , , and T.
Correspondence re: Y. Chen et al., DNA Vaccines Encoding Full-Length or Truncated Neu Induce Protective Immunity against Neu-expressing Mammary Tumors. Cancer Res., 58: 1965-1971,
Cancer Res., September 1, 1999; 59(17): 4471 - 4472.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Nishikawa, K. Tanida, H. Ikeda, M. Sakakura, Y. Miyahara, T. Aota, K. Mukai, M. Watanabe, K. Kuribayashi, L. J. Old, et al.
Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity
PNAS, December 4, 2001; 98(25): 14571 - 14576.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.